33results about How to "Inhibitory effect" patented technology

A security device for SIP communications operates to inhibit the effect of malicious attacks and / or inadvertent erroneous events on the provision of SIP-based services within a private network and between private and public networks. The security device acts as a conventional Firewall, NAT and PAT to isolate SIP User Agents on the private network from SIP User Agents on the public network and to Blacklist undesired callers. Also, the security device preferably includes a virus scanner to scan attachments to sessions and / or other communications to identify and block virus contaminated data and the security device includes a hardened SIP stack to scan for and detect malformed SIP messages to prevent malicious attacks and / or inadvertent erroneous messages from adversely impacting the operation of SIP services.

This invention relates to a dietary supplement which is a phytochemical composition. This composition is capable of controlling inflammatory conditions and preventing and curing cancer in mammals. The composition comprises a synergistic mixture of standardized Boswellia extract, salts of glucosamine, and curcuminoids optionally containing bromelain, chondroitin, methylsulphonylmethane, resveratrol, extracts of white Willow and ginger, and quercetin.

An object of the present invention is to provide a duplex threaded body having a right-handed thread and a left-handed thread on the circumferential surface of a single solid member. In addition, an object of the present invention is to provide a single-nut or double-nut type internally-threaded body that demonstrates a locking effect even at an intermediate position without substantially loosening by using a combination of a duplex externally-threaded body and one or more internally-threaded bodies. Moreover, an object of the present invention is to provide a screw structure in which a pair of internally-threaded bodies can only be removed by destruction once they are mutually coupled when screwed onto a duplex externally-threaded body, thereby making it possible to impart tamper-proof characteristics in addition to a locking effect. The duplex externally-threaded body of the present invention has, on the outer circumferential surface of a rod-like member, an overlapping region in which a clockwise spiral right-handed thread and a counter-clockwise spiral left-handed thread are provided in at least an overlapping manner. Moreover, the present invention makes it possible to use, alone or in combination, a right-handed internally-threaded body in which a right-handed thread is formed, and a left-handed internally-threaded body in which a left-handed thread is formed, that are screwed onto a duplex externally-threaded body.

Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase.

A process for the production of highly purified water from Fischer-Tropsch reaction water includes distillation as a primary treatment stage, evaporation as a secondary treatment stage, aerobic treatment as a tertiary treatment stage, solid-liquid separation as a quartic treatment stage, and membrane separation as a final treatment stage.

Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

The invention provides a photovoltaic device and method of manufacturing the same. The photovoltaic device of the invention includes a semiconductor structure assembly and a protection layer. The semiconductor structure assembly has a plurality of side surfaces, and includes a p-n junction, an n-p junction, a p-i-n junction, an n-i-p junction, a tandem junction or a multi-junction. In particular, the protection layer is formed to overlay the sides of the semiconductor structure assembly. Thereby, the protection layer can effectively inhibit the potential-induced degradation effect of the photovoltaic device of the invention.

The invention provides a method for detecting apoptosis in a myeloid cell comprising detecting an alteration in any one of: i) a Survivin polypeptide having an amino acid sequence as set out in SEQ ID NO: 1; ii) a polypeptide having at least 80% homology with i); iii) a nucleic acid encoding a polypeptide having the sequence set out in i) or ii); iv) a nucleic acid which hybridises under stringent conditions to the sequence set out in iii); or v) the complement of iii) or iv). The invention accordingly provides a method of modulating apoptosis in neutrophils by modulating Survivin gene expression and a method of treating inflammatory disease by modulating Survivin gene expression or function.

It is intended to provide a novel agent for promoting the recovery from dysfunction after the onset of a central neurological disease or an agent for enhancing and / or promoting the effect of rehabilitation for functional recovery. Namely, an agent for promoting the recovery from dysfunction after the onset of a central neurological disease which contains, as the active ingredient, a compound capable of simultaneously and selectively enhancing neurotransmission by serotonin and neurotransmission by norepinephrine; and an agent for enhancing and / or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease which contains, as the active ingredient, a compound capable of simultaneously and selectively enhancing neurotransmission by serotonin and neurotransmission by norepinephrine. It is useful to provide the excellent agent for promoting the recovery from dysfunction after the onset of a central neurological disease and the agent for enhancing and / or promoting the effect of rehabilitation for functional recovery as described above. These drugs are also useful as safe drugs because of being free from anticholinergic effect causing side effects, drug dependence or effects on the circulatory organs.

A reduction inhibitory agent for active-oxygen eliminating activity comprises trehalose as an effective ingredient. A method for inhibiting the reduction of active-oxygen eliminating activity comprises incorporating either trehalose or the reduction inhibitory agent into plant edible products and / or plant antioxidants. A composition is provided that reduces the active-oxygen eliminating activity of plant edible products and / or plant antioxidants.

The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

The present invention provides novel pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect.

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

To provide a bisphenol A production process which can inhibit deterioration of the cation exchange resin catalyst used in the reaction step to enable long-time stabilized production of bisphenol A. Means for Implementation: A process for producing bisphenol A by reacting the raw materials acetone and phenol in the presence of a catalyst, in which one of the following means (1)-(3) is used: (1) In supplying to the reaction step the raw materials and the acetone recovered from the reaction step, the lower alcohol concentration in the whole amount of acetone supplied to the reaction step is adjusted to be not more than 100 ppm. (2) In supplying to the reaction step the raw materials and those recovered from the reaction step, the lower alcohol concentration in the reaction solution discharged from the reaction step is adjusted to be not more than 30 ppm. (3) In supplying the raw materials and the recovered acetone to the reaction step, at least the recovered acetone in the whole supply of acetone to the reaction step is refined before supplied to the reaction step to remove the lower alcohols contained as impurities.

The invention aims at providing a platinum black material, without using an expensive and rare material, which is excellent in CO poisoning inhibiting effect, H2S poisoning inhibiting effect, SO4 poisoning inhibiting effect and HCHO poisoning inhibiting effect, and a method for fluorinating platinum black. The platinum black material is characterized by fluorine adsorbed on its surface. The method for fluorinating platinum black is characterized by allowing platinum black to stand in a mixed gas atmosphere of n inert gas and fluorine in a low-pressure chamber to make fluorine adsorbed on the surface of the platinum black.

A method is described for the identification of multi-subunit biocomplex drug targets. The method includes identifying a target that performs a biological function, wherein the target comprises one or more subunits, wherein a minimum number of the one or more subunits is inactivated to inhibit the biological function. The method includes selecting a drug that binds specifically to each subunit of the one or more subunits with a target probability. The method describes a relationship between inhibition efficiency of the drug and total number of the one or more subunits using a binomial distribution, wherein the inhibition efficiency comprises a probability that the delivered drug blocks the biological function. The method includes confirming empirically the relationship using an experimental target. The method includes administering the drug to the target to treat a multi-drug resistant disease, wherein the target comprises a biological complex in a mammalian subject.

The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.

A novel thermoacidophilic pullulanase (Tk-PUL) from hyperthermophilic archaeon Thermococcus kodakaraensis KOD1 is described here that efficiently hydrolyzes starch under industrial conditions in the absence of any additional metal ions. The gene encoding Tk-PUL was cloned and expressed in E. coli cells. The purified recombinant enzyme possesses the following properties;shows both pullulanase and α-amylase activitiesdisplays highest activity at 95-100° C.active over a broad pH range (3.0-8.5) with optimum working pH 3.5stable for several hours at 90° C. and displays a half-life of 45 minutes at 100° C.activity and stability are independent of calcium and other metal ionshydrolyzes maltotrioseMoreover, recombinant Tk-PUL can be used for single step liquefaction and saccharification of corn starch (without any α-amylase or β-amylase) at pH 4.2 in the absence of calcium.

An alkynyl-substituted azasugar derivative and a drug containing the same as an active ingredient are disclosed. This drug is useful as a preventive or remedy for insulin-independent diabetes, rheumatoid arthritis, osteoarthritis, sepsis, acquired immune deficiency syndrome (AIDS), graft-versus-host disease (GVHD), asthma, atopic dermatitis, and ulcerative colitis.

The invention belongs to the field of chemical medicine, and relates to application of 1-[N-(3,5-bis(2-(2-methoxyethoxy)ethoxy)ethoxy)benzyl-2,3,3-trimethyl-5-sulfo-3H-indole]-5-[N-carboxybenzyl-2,3,3-trimethyl-5-sulfo-3H-indole]-5-pentacyaninebromide dye (Cy5-671 as hereinafter referred to preparation) for preparing an anti-tumor medicine. MTT results show that Cy5-671 can significantly inhibit the cell viability of colorectal cancer cell lines HCT116 and SW480. Animal experiment results show that Cy5-671 significantly inhibits the growth of human colorectal cancer cell line HCT116 BALB / C nude mouse subcutaneous tumor-bearing, and can be used for preparing antitumor drugs. The Cy5-671 disclosed by the invention can be developed as a novel anti-tumor drug or an auxiliary component thereof,so that the tumor inhibition effect is remarkable, and a new treatment way and means are provided for tumor treatment.

It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

A lens with an optical area to increase a defocus image refractive powers is disclosed. A central optical zone of the lens includes a non-circular optical area, and a defocus area formed on a part thereof other than the optical area. An outer surface of the peripheral optical zone is aspheric, so that the original space of the central optical zone can be effectively used to increase the defocus image area of the retina of eye ball and light passing the peripheral optical zones can create different amounts of peripheral blurring areas in front of different areas of the retina; this defocusing of the images, providing more controlled amount of myopic defocus to the retina, which acts as a putative cue to slow myopic eye growth.

The invention discloses R-4-hydroxyl-2-(2-hydroxy phenyl)-butyric acid as well as a preparation and application thereof. The compound and the preparation thereof can be used for remarkably inhibiting phytophthora Infestans pathogens and effectively preventing and treating the phytophthora Infestans of solanaceae plants.

The invention describes an aryl-2,2′-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2′-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.

A method for treating keloids, hypertrophic scars and / or wounds and / or other skin conditions, the method comprising: delivering a pharmaceutically effective amount of a pharmaceutical composition to the keloids, hypertrophic scars and / or wounds and / or other skin conditions, wherein the pharmaceutical composition comprises a mixture of cross-linked glycosaminoglycans and taurolidine and / or one or more taurolidine derivatives.

The invention discloses a novel quinazoline derivative LU1501 and a preparing method thereof, wherein the quinazoline derivative has a chemical name of N-[(4-fluorophenyl)methyl]-4-N-{7-methoxy-6-[(2-pyrrolidin-1-yl)hydroxyethyl]quinazoline-4-yl}phen-1,4-diamine. The quinazoline derivative and a pharmaceutically acceptable salt, a solvate and a hydrate thereof have excellent anti-tumor activity in vitro and in vivo to MCF-7, SK-BR-3, A549, HCT 116, U-118 MG; U-87 MG and MDA-MB-468, and have preferable application prospects on preparing anti-tumor drugs.

Disclosed in the present invention are a 2-(1,2,4-triazolyl)benzoyl arylamine active compound for inhibiting a wheat take-all pathogen, and a preparation method therefor. The active compound has a structure as shown in formula I. R1, R3, and R4 are —H, —F, —Cl, —Br, —I, —CN, —NO2, —CF3, —CHO, —C1-C4 alkyl groups, or —C1-C4 haloalkyl groups, or —O—R5; R2 is —H, —F, —Cl, —Br, —I, —CN, —CF3, —CHO, —C1-C4 alkyl groups, or —C1-C4 haloalkyl groups, or —O—R5; X is —F, —Cl, —Br, —I, —CN, —NO2, —CF3, or —COOR6; Y is —H, —F, —Cl, —Br, —I, —CN, —NO2, —CF3, or —COOR6; R5 is —C1-C4 alkyl groups, or —C1-C4 haloalkyl groups; R6 is —C1-C4 alkyl groups, or —C1-C4 haloalkyl groups. The compound I has an excellent inhibition effect on the wheat take-all pathogen and can be applied to prevention and treatment of wheat take-all.

This invention relates to benzomorpholine derivatives typified by a compound represented by general formula (VIII) or pharmaceutically acceptable salts thereof and platelet aggregation inhibitors comprising the same. The compounds of the present invention have a strong inhibitory effect of platelet aggregation, so that they are effective for treating and preventing diseases in which thrombus is involved.